Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1

This computational study aims to explore the inhibition property of two plant-derived AMPs (antimicrobial peptides), defensin VvK1 and snakin-1, against SHV-1 β-lactamase from Klebsiella pneumoniae by molecular docking, MDS (molecular dynamics simulation) and MM-PB/GBSA (Molecular Mechanics-Poisson-...

Full description

Saved in:
Bibliographic Details
Main Authors: Manisha Mandal, Shyamapada Mandal
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2025-06-01
Series:Biomedical Analysis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950435X25000320
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850111754880679936
author Manisha Mandal
Shyamapada Mandal
author_facet Manisha Mandal
Shyamapada Mandal
author_sort Manisha Mandal
collection DOAJ
description This computational study aims to explore the inhibition property of two plant-derived AMPs (antimicrobial peptides), defensin VvK1 and snakin-1, against SHV-1 β-lactamase from Klebsiella pneumoniae by molecular docking, MDS (molecular dynamics simulation) and MM-PB/GBSA (Molecular Mechanics-Poisson-Boltzmann/Generalized Born Surface Area) analysis. The AMPs (defensin VvK1 and snakin-1) were docked to SHV-1 β-lactamase for intermolecular (protein-peptide) interaction analysis and binding affinity prediction. SHV-1-defensin-VvK1 and SHV-1-snakin-1 complexes were subjected to MM-PB/GBSA free binding energy calculations after 10 ns MDS. To compare the efficacy of stronger AMP, defensin-VvK1, with reference inhibitor, cymal-6, 50 ns MDS was accomplished. Safety profiles of the AMPs were predicted by allergenicity and toxicity testing. Docking study revealed lower binding free energy for top-ranked SHV-1-snakin-1 complex than SHV-1-defensin-VvK1. SHV-1-defensin-VvK1 was energetically stronger than SHV-1-snakin-1 at 10 ns MDS run. After 50 ns MDS run, defensin-VvK1 (MM-PBSA: −70.73 ± 0.57 kcal/mol; MM-GBSA: −62.53 ± 0.43 kcal/mol) showed stronger efficacy than cymal-6 (MM-PBSA: −21.46 ± 0.50 kcal/mol; MM-GBSA: −26.79 ± 0.34 kcal/mol) against SHV-1. Both the AMPs demonstrated acceptable physicochemical properties, and were found non-allergenic and non-toxic. Thus, current in silico study validated the anti-Klebsiella pneumoniae activity of naturally occurring AMPs (snakin-1 and defensin-VvK1), wherein defensin-VvK1 showed higher activity against SHV-1 β-lactamase. Therefore, the AMPs currently being studied could be used as alternative biotherapeutic agents to combat life-threatening infections caused by antibiotic resistant bacterial pathogens. Overall, the findings can be translated into the process of designing and developing peptide-based therapeutics by targeting bacterial β-lactamases.
format Article
id doaj-art-3998eb7a2ccd4d01afbe939440b908df
institution OA Journals
issn 2950-435X
language English
publishDate 2025-06-01
publisher KeAi Communications Co., Ltd.
record_format Article
series Biomedical Analysis
spelling doaj-art-3998eb7a2ccd4d01afbe939440b908df2025-08-20T02:37:33ZengKeAi Communications Co., Ltd.Biomedical Analysis2950-435X2025-06-0122395010.1016/j.bioana.2025.06.001Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1Manisha Mandal0Shyamapada Mandal1Department of Physiology, MGM Medical College, Kishanganj, Bihar 855107, IndiaDepartment of Zoology, University of Gour Banga, West Bengal, Malda 732103, India; Corresponding author.This computational study aims to explore the inhibition property of two plant-derived AMPs (antimicrobial peptides), defensin VvK1 and snakin-1, against SHV-1 β-lactamase from Klebsiella pneumoniae by molecular docking, MDS (molecular dynamics simulation) and MM-PB/GBSA (Molecular Mechanics-Poisson-Boltzmann/Generalized Born Surface Area) analysis. The AMPs (defensin VvK1 and snakin-1) were docked to SHV-1 β-lactamase for intermolecular (protein-peptide) interaction analysis and binding affinity prediction. SHV-1-defensin-VvK1 and SHV-1-snakin-1 complexes were subjected to MM-PB/GBSA free binding energy calculations after 10 ns MDS. To compare the efficacy of stronger AMP, defensin-VvK1, with reference inhibitor, cymal-6, 50 ns MDS was accomplished. Safety profiles of the AMPs were predicted by allergenicity and toxicity testing. Docking study revealed lower binding free energy for top-ranked SHV-1-snakin-1 complex than SHV-1-defensin-VvK1. SHV-1-defensin-VvK1 was energetically stronger than SHV-1-snakin-1 at 10 ns MDS run. After 50 ns MDS run, defensin-VvK1 (MM-PBSA: −70.73 ± 0.57 kcal/mol; MM-GBSA: −62.53 ± 0.43 kcal/mol) showed stronger efficacy than cymal-6 (MM-PBSA: −21.46 ± 0.50 kcal/mol; MM-GBSA: −26.79 ± 0.34 kcal/mol) against SHV-1. Both the AMPs demonstrated acceptable physicochemical properties, and were found non-allergenic and non-toxic. Thus, current in silico study validated the anti-Klebsiella pneumoniae activity of naturally occurring AMPs (snakin-1 and defensin-VvK1), wherein defensin-VvK1 showed higher activity against SHV-1 β-lactamase. Therefore, the AMPs currently being studied could be used as alternative biotherapeutic agents to combat life-threatening infections caused by antibiotic resistant bacterial pathogens. Overall, the findings can be translated into the process of designing and developing peptide-based therapeutics by targeting bacterial β-lactamases.http://www.sciencedirect.com/science/article/pii/S2950435X25000320SHV-1 β-lactamaseKlebsiella pneumoniaeAntimicrobial peptidesMolecular dockingMM-PB/GBSA binding free energy
spellingShingle Manisha Mandal
Shyamapada Mandal
Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
Biomedical Analysis
SHV-1 β-lactamase
Klebsiella pneumoniae
Antimicrobial peptides
Molecular docking
MM-PB/GBSA binding free energy
title Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
title_full Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
title_fullStr Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
title_full_unstemmed Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
title_short Molecular docking, molecular dynamics simulation and MM-PB/GBSA analysis for the inhibition of Klebsiella pneumoniae SHV-1 β-lactamase using antimicrobial peptides defensin VvK1 and snakin-1
title_sort molecular docking molecular dynamics simulation and mm pb gbsa analysis for the inhibition of klebsiella pneumoniae shv 1 β lactamase using antimicrobial peptides defensin vvk1 and snakin 1
topic SHV-1 β-lactamase
Klebsiella pneumoniae
Antimicrobial peptides
Molecular docking
MM-PB/GBSA binding free energy
url http://www.sciencedirect.com/science/article/pii/S2950435X25000320
work_keys_str_mv AT manishamandal moleculardockingmoleculardynamicssimulationandmmpbgbsaanalysisfortheinhibitionofklebsiellapneumoniaeshv1blactamaseusingantimicrobialpeptidesdefensinvvk1andsnakin1
AT shyamapadamandal moleculardockingmoleculardynamicssimulationandmmpbgbsaanalysisfortheinhibitionofklebsiellapneumoniaeshv1blactamaseusingantimicrobialpeptidesdefensinvvk1andsnakin1